Wyeth's Xyntha gets FDA OK

02/21/2008 | MarketWatch

The FDA on Thursday announced that it has cleared Wyeth's drug Xyntha as treatment for rare blood-clotting disorder hemophilia A. The drug is indicated for regulating and preventing spontaneous or post-injury bleeding in patients with the disorder.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL